Kazuyuki Shimizu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuyuki Shimizu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Junji Itoh
2 shared publications- Chihiro Shimazaki
Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan
1 shared publication Eiichi Nagura
1 shared publicationHirokazu Murakami
1 shared publicationHiroshi Kosugi
1 shared publication- Hiroyuki Hata
Department of Hematology, Faculty of Medical Sciences, Kumamoto University, Kumamoto 860‑8556, Japan
1 shared publication
Latest Publications
- 1 April 2010
- Vol. 51 (4) , 245-52
[Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Recently, a highly sensitive assay (FREELITE) capable of measuring serum immunoglobulin-free light chains (FLC) was developed. An abnormal kappa/lambda ratio supports the presence of clonal plasma cell expansion. Using this assay, we measured serum and urine samples of 178 healthy volunteers, 184 patients with polyclonal gamma-globulinemia and 150 patients with monoclonal gamma-globulinemia. The diagnostic sensitivity of the FLC assays for monoclonal gammopathies was 88.0% and the specificity for healthy volunteers and polyclonal gammopathies was 96.1%. The minimal detection sensitivity of this assay for serum FLC was 0.3 mg/l and was greater than 100-fold more sensitive than serum protein electrophoresis (SPE). The combination of FLC with SPE and immunoelectrophoresis identified 99% of patients with monoclonal gammopathies. Effective treatment often leads to a more rapid reduction of the involved FLC level relative to the intact immunoglobulin or total light chain concentration because the half-life of FLC is <6 hours. These observations suggest that FREELITE is useful for diagnosis, disease monitoring and assessment of response to treatment in patients with monoclonal gammopathies such as multiple myeloma and AL amyloidosis.
- 1 April 2010
- Vol. 51 (4) , 245-52
[Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Recently, a highly sensitive assay (FREELITE) capable of measuring serum immunoglobulin-free light chains (FLC) was developed. An abnormal kappa/lambda ratio supports the presence of clonal plasma cell expansion. Using this assay, we measured serum and urine samples of 178 healthy volunteers, 184 patients with polyclonal gamma-globulinemia and 150 patients with monoclonal gamma-globulinemia. The diagnostic sensitivity of the FLC assays for monoclonal gammopathies was 88.0% and the specificity for healthy volunteers and polyclonal gammopathies was 96.1%. The minimal detection sensitivity of this assay for serum FLC was 0.3 mg/l and was greater than 100-fold more sensitive than serum protein electrophoresis (SPE). The combination of FLC with SPE and immunoelectrophoresis identified 99% of patients with monoclonal gammopathies. Effective treatment often leads to a more rapid reduction of the involved FLC level relative to the intact immunoglobulin or total light chain concentration because the half-life of FLC is <6 hours. These observations suggest that FREELITE is useful for diagnosis, disease monitoring and assessment of response to treatment in patients with monoclonal gammopathies such as multiple myeloma and AL amyloidosis.
- Open Access
- 31 March 2009
- Published by Wiley in American Journal of Hematology
- Vol. 84 (6) , 382-385
A possible link between Trousseau's syndrome and tissue factor producing plasma cells
- 31 March 2009
- Published by Wiley in American Journal of Hematology
- Vol. 84 (6) , 382-385
Open AccessA possible link between Trousseau's syndrome and tissue factor producing plasma cells